Limits...
Comparison of somnolence associated with asenapine, olanzapine, risperidone, and haloperidol relative to placebo in patients with schizophrenia or bipolar disorder.

Gao K, Mackle M, Cazorla P, Zhao J, Szegedi A - Neuropsychiatr Dis Treat (2013)

Bottom Line: This study assessed the median time to onset, duration, and rate of somnolence associated with asenapine and other antipsychotics in both indications.In the adjunctive therapy for BPD cohort, the incidence, median time to onset, and duration of somnolence with asenapine and placebo were 24.0% versus 10.2%, 1.5 days versus 2 days, and 12.5 days versus 7 days, respectively.Only asenapine and olanzapine had significantly higher rates of somnolence relative to placebo.

View Article: PubMed Central - PubMed

Affiliation: Department of Psychiatry, Mood and Anxiety Clinic in the Mood Disorders Program, Case Western Reserve University, School of Medicine, Cleveland, OH, USA;

ABSTRACT

Background: Patients with schizophrenia or bipolar disorder (BPD) may be differentially sensitive to antipsychotics. This study assessed the median time to onset, duration, and rate of somnolence associated with asenapine and other antipsychotics in both indications.

Methods: Ten clinical trials (n = 4786) were analyzed as five cohorts pooled according to indication and study design.

Results: In the short-term schizophrenia cohort, the incidence of somnolence was 13.1%, 19.1%, 8.5% 5.2%, and 6.9% with asenapine, olanzapine, risperidone, haloperidol, and placebo, respectively. Median time to onset of somnolence was 2 days for asenapine and olanzapine, and 6, 3, and 7 days for risperidone, haloperidol, and placebo, respectively. Median duration was 15 days for asenapine and olanzapine, and 3, 22.5, and 4.5 days for risperidone, haloperidol, and placebo, respectively. In the long-term schizophrenia cohort, the incidence, time to onset, and duration of somnolence with asenapine and olanzapine were 18.4% versus 19.6%, 9.0 days versus 12 days, and 22 days versus 21 days, respectively. In schizophrenia with persistent negative symptoms, the incidence, median time to onset, and duration of somnolence with asenapine and olanzapine were 18.5% versus 21.1%, 9.0 days versus 7.5 days, and 25.0 days versus 41.5 days, respectively. In the monotherapy for BPD cohort, the incidence of somnolence with asenapine, olanzapine, and placebo was 23.8%, 26.4%, and 6.4%, respectively. Median time to onset and duration of somnolence with asenapine, olanzapine, and placebo were 1, 2, and 2 days, respectively, and 7, 8.5, and 5 days. In the adjunctive therapy for BPD cohort, the incidence, median time to onset, and duration of somnolence with asenapine and placebo were 24.0% versus 10.2%, 1.5 days versus 2 days, and 12.5 days versus 7 days, respectively.

Conclusion: In the short-term schizophrenia cohort, time to onset and duration of somnolence with asenapine was similar to that with olanzapine and haloperidol. Only asenapine and olanzapine had significantly higher rates of somnolence relative to placebo. The time to onset, duration, and incidence of somnolence with asenapine and olanzapine was similar in patients with long-term schizophrenia and those with BPD. Patients with BPD were more sensitive than those with schizophrenia to asenapine and olanzapine.

No MeSH data available.


Related in: MedlinePlus

Median duration of somnolence in short-term studies of patients with schizophrenia or bipolar 1 disorder with baseline (A) anxiety (PANSS G2 <4 or ≥4), (B) anxiety/depression (PANSS MF anxiety/depression < 16 or ≥16), and (C) depression (PANSS G6 < 4 or ≥4).Abbreviations: ASE, asenapine; OLA, olanzapine; PBO, placebo; ST, short-term; PANSS, Positive and Negative Syndrome Scale.
© Copyright Policy
Related In: Results  -  Collection


getmorefigures.php?uid=PMC3755703&req=5

f4-ndt-9-1145: Median duration of somnolence in short-term studies of patients with schizophrenia or bipolar 1 disorder with baseline (A) anxiety (PANSS G2 <4 or ≥4), (B) anxiety/depression (PANSS MF anxiety/depression < 16 or ≥16), and (C) depression (PANSS G6 < 4 or ≥4).Abbreviations: ASE, asenapine; OLA, olanzapine; PBO, placebo; ST, short-term; PANSS, Positive and Negative Syndrome Scale.

Mentions: The median time to onset of somnolence (Figure 2A) was significantly shorter with asenapine (2.0 days; P<0.01) and olanzapine (2.0 days; P<0.0001) compared with placebo (7.0 days). The median times to onset with risperidone (6.0 days) and haloperidol (3.0 days) were not significantly different from placebo. The median duration of somnolence (Figure 3) with asenapine was numerically longer (15 days) than with placebo (4.5 days) or risperidone (3 days), similar to olanzapine (15 days), and numerically less than haloperidol (22.5 days). Duration of somnolence was longer in patients in the olanzapine group with elevated baseline anxiety (PANSS G2 ≥4, Figure 4A). In the asenapine and olanzapine groups, the median duration of somnolence was prolonged in the subgroup of patients with PANSS MF anxiety/depression ≥16 (Figure 4B).


Comparison of somnolence associated with asenapine, olanzapine, risperidone, and haloperidol relative to placebo in patients with schizophrenia or bipolar disorder.

Gao K, Mackle M, Cazorla P, Zhao J, Szegedi A - Neuropsychiatr Dis Treat (2013)

Median duration of somnolence in short-term studies of patients with schizophrenia or bipolar 1 disorder with baseline (A) anxiety (PANSS G2 <4 or ≥4), (B) anxiety/depression (PANSS MF anxiety/depression < 16 or ≥16), and (C) depression (PANSS G6 < 4 or ≥4).Abbreviations: ASE, asenapine; OLA, olanzapine; PBO, placebo; ST, short-term; PANSS, Positive and Negative Syndrome Scale.
© Copyright Policy
Related In: Results  -  Collection

Show All Figures
getmorefigures.php?uid=PMC3755703&req=5

f4-ndt-9-1145: Median duration of somnolence in short-term studies of patients with schizophrenia or bipolar 1 disorder with baseline (A) anxiety (PANSS G2 <4 or ≥4), (B) anxiety/depression (PANSS MF anxiety/depression < 16 or ≥16), and (C) depression (PANSS G6 < 4 or ≥4).Abbreviations: ASE, asenapine; OLA, olanzapine; PBO, placebo; ST, short-term; PANSS, Positive and Negative Syndrome Scale.
Mentions: The median time to onset of somnolence (Figure 2A) was significantly shorter with asenapine (2.0 days; P<0.01) and olanzapine (2.0 days; P<0.0001) compared with placebo (7.0 days). The median times to onset with risperidone (6.0 days) and haloperidol (3.0 days) were not significantly different from placebo. The median duration of somnolence (Figure 3) with asenapine was numerically longer (15 days) than with placebo (4.5 days) or risperidone (3 days), similar to olanzapine (15 days), and numerically less than haloperidol (22.5 days). Duration of somnolence was longer in patients in the olanzapine group with elevated baseline anxiety (PANSS G2 ≥4, Figure 4A). In the asenapine and olanzapine groups, the median duration of somnolence was prolonged in the subgroup of patients with PANSS MF anxiety/depression ≥16 (Figure 4B).

Bottom Line: This study assessed the median time to onset, duration, and rate of somnolence associated with asenapine and other antipsychotics in both indications.In the adjunctive therapy for BPD cohort, the incidence, median time to onset, and duration of somnolence with asenapine and placebo were 24.0% versus 10.2%, 1.5 days versus 2 days, and 12.5 days versus 7 days, respectively.Only asenapine and olanzapine had significantly higher rates of somnolence relative to placebo.

View Article: PubMed Central - PubMed

Affiliation: Department of Psychiatry, Mood and Anxiety Clinic in the Mood Disorders Program, Case Western Reserve University, School of Medicine, Cleveland, OH, USA;

ABSTRACT

Background: Patients with schizophrenia or bipolar disorder (BPD) may be differentially sensitive to antipsychotics. This study assessed the median time to onset, duration, and rate of somnolence associated with asenapine and other antipsychotics in both indications.

Methods: Ten clinical trials (n = 4786) were analyzed as five cohorts pooled according to indication and study design.

Results: In the short-term schizophrenia cohort, the incidence of somnolence was 13.1%, 19.1%, 8.5% 5.2%, and 6.9% with asenapine, olanzapine, risperidone, haloperidol, and placebo, respectively. Median time to onset of somnolence was 2 days for asenapine and olanzapine, and 6, 3, and 7 days for risperidone, haloperidol, and placebo, respectively. Median duration was 15 days for asenapine and olanzapine, and 3, 22.5, and 4.5 days for risperidone, haloperidol, and placebo, respectively. In the long-term schizophrenia cohort, the incidence, time to onset, and duration of somnolence with asenapine and olanzapine were 18.4% versus 19.6%, 9.0 days versus 12 days, and 22 days versus 21 days, respectively. In schizophrenia with persistent negative symptoms, the incidence, median time to onset, and duration of somnolence with asenapine and olanzapine were 18.5% versus 21.1%, 9.0 days versus 7.5 days, and 25.0 days versus 41.5 days, respectively. In the monotherapy for BPD cohort, the incidence of somnolence with asenapine, olanzapine, and placebo was 23.8%, 26.4%, and 6.4%, respectively. Median time to onset and duration of somnolence with asenapine, olanzapine, and placebo were 1, 2, and 2 days, respectively, and 7, 8.5, and 5 days. In the adjunctive therapy for BPD cohort, the incidence, median time to onset, and duration of somnolence with asenapine and placebo were 24.0% versus 10.2%, 1.5 days versus 2 days, and 12.5 days versus 7 days, respectively.

Conclusion: In the short-term schizophrenia cohort, time to onset and duration of somnolence with asenapine was similar to that with olanzapine and haloperidol. Only asenapine and olanzapine had significantly higher rates of somnolence relative to placebo. The time to onset, duration, and incidence of somnolence with asenapine and olanzapine was similar in patients with long-term schizophrenia and those with BPD. Patients with BPD were more sensitive than those with schizophrenia to asenapine and olanzapine.

No MeSH data available.


Related in: MedlinePlus